Axsome Therapeutics, Inc. (AXSM) Financial Statements
Axsome Therapeutics, Inc. (AXSM) reported trailing twelve-month revenue of $776.6M (up 56.9% year on year) and net income of -$191.6M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$72.0M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AXSMAxsome Therapeutics, Inc.Follow AXSM — free
—
Price chart with a free account
- Market cap
- 7.6B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 2 Nov, in 9 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|
| Revenue | 50.0 | 270.6 | 385.7 | 638.5 | 776.6 | |
| Gross profit | 44.8 | 244.5 | 352.4 | 591.0 | 724.0 | |
| Research & development | 57.9 | 97.9 | 187.1 | 183.3 | 187.9 | |
| Operating income | -179.8 | -231.8 | -280.6 | -166.8 | -186.1 | |
| Pre-tax income | -187.1 | -238.3 | -287.1 | -183.7 | -191.1 | |
| Income tax | 0.0 | 1.0 | 0.1 | -0.5 | 0.6 | |
| Net income | -187.1 | -239.2 | -287.2 | -183.2 | -191.6 | |
| Diluted EPS ($) | -4.60 | -5.27 | -5.99 | -3.68 | -3.74 | |
| Diluted shares (mn) | 40.7 | 45.4 | 47.9 | 49.7 | — |
USD millions · SEC XBRL
Axsome Therapeutics, Inc. — questions
- What is Axsome Therapeutics, Inc.'s revenue?
- $776.6M over the twelve months to 2026-06-30, up 56.9% year on year, from its 10-Q and 10-K filings.
- What is Axsome Therapeutics, Inc.'s net income?
- -$191.6M over the twelve months to 2026-06-30.
- What is Axsome Therapeutics, Inc.'s free cash flow?
- -$72.0M over the twelve months to 2026-06-30.
- What are Axsome Therapeutics, Inc.'s diluted earnings per share?
- $-3.74 over the twelve months to 2026-06-30.
Every figure on this page comes from Axsome Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.